Purpose/Objectives: A percentage of patients receiving stereotactic radiosurgery (SRS)/fractionated stereotactic radiotherapy (FSRT) for Schwannomas initially.

Slides:

Advertisements

Similar presentations

FACET - European Journal of Cancer Care March 2006 slides available at: Stereotactic radiosurgery Gordon, K. 1.

Advertisements

Yoshiya Yamada M.D., Ilya Laufer M.D., Brett W. Cox M.D.,

CARBON ION THERAPY FOR SACRAL CHORDOMAS

Management of Acoustic Neuroma NEMROCK Experience Mohamed Abdulla (M.D.) Ass. Professor of Clinical Oncology Kasr El-Aini School of Medicine.

Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.

Stereotactic Radiosurgery Jimmy Johannes Physics 335 – Spring 2004 Final Presentation

Radiotherapy for Brain Tumours What do I need to know? Dr Matthew Foote Radiation Oncologist Princess Alexandra Hospital Queensland.

Surgery Surgery is the initial therapy for nearly all patients with brain tumors and can cure most benign tumors, including meningiomas Goal : to remove.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Intra-Operative Radiation Therapy for Treatment of Early Stage Breast Cancer: Short Term Results from a Single Institution Clinical Trial Using Electronic.

Comparison of MRI Perfusion and PET-CT in Differentiating Brain Tumor Progression from Radiation Injury after Cranial Irradiation T. Jonathan Yang, M.D.

Vertebral Fractures After Stereotactic Ablative Radiotherapy of Lung Tumors Todd A. Aguilera MD PhD 1, Nicholas Trakul MD PhD 2, David B. Shultz MD PhD.

Learn More At: Northwest Hospital Gamma Knife Center Dr. Sandra Vermeulen, M.D. Swedish Cancer Institute Northwest Hospital Gamma.

Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.

Acoustic Neuroma (Vestibular Schwannoma) Diagnosis and treatment

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

1 Overview of Gamma Knife ® Surgery Dr. Sandra Vermeulen, M.D. Swedish Cancer Institute Northwest Hospital Gamma Knife Center Seattle, Washington Learn.

Learn More At: Dose-Response and Dose- Complications Relationships in Stereotactic Radiosurgery for Trigeminal Neuralgia Sandra.

Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin- Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic.

What’s up with Acoustic Neuromas? Nancy Fuller, M.D. PCC September 27, 2006.

We retrospectively analyzed 58 patients with ONSM treated between on a dedicated 6 MV stereotactic LINAC. All cases were discussed in a multidisciplinary.

Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,

Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy.

NF2 and Hearing Preservation After Gamma Knife Treatment Reem Emad, MD Radiation Oncologist National Cancer Institute, Cairo University And Gamma Knife.

Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy.

A Comparison Between Two Leading Stereotactic Platforms in the Treatment of Multiple Metastases Sandra Vermeulen MD, James Raisis.

Gamma Knife Kelly & Tarah.

Outcomes of Stereotactic Ablative Radiotherapy (SABR) for a Second Primary Lung Cancer (SPLC): Evidence in Support of Routine CT Surveillance C. J.A. Haasbeek,

Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung.

T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec,

Palliative Single 8 Gy Radiotherapy for Symptomatic Aggressive Lymphomas 2666 Ａ -408 Oguchi M, Eba J, Tanaka O, Kozuka T, Murofushi K, Toshiyasu T, Tsurugai.

M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.

Increased Local Control of Lung and Liver Tumors Associated with Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response Relationship.

ENDOVASCULAR TREATMENT (EVT) OF BRAIN AND DURAL MALFORMATIONS (AVM) USING ONYX IN A SINGLE CENTER EXPERIENCE,N.SOUROUR MD,M.MUSACCHIO MD,A.LEBEDINSKY MD,N.HIROTA.

SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.

THE IMPLEMENTATION OF ABLATIVE HYPOFRACTIONATED RADIOTHERAPY FOR STEREOTACTIC TREATMENTS IN THE BRAIN AND BODY: OBSERVATIONS ON EFFICACY AND TOXICITY IN.

Authors: Syed H. Jafri ¹, Angel I. Blanco¹, Bonnie A. Labdi², Shan Guo¹. UT Houston department of medicine, Division of Oncology Department of Pharmacy.

Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

Toxicity of Gamma Knife Radiosurgery in the Treatment of Intracranial Tumors in Patients With Collagen Vascular Diseases or Multiple Sclerosis Dot Lowell,

Gamma Knife Radiosurgery for Large Vestibular Schwannomas: A Canadian Experience Zeiler FA1, Bigder M1, Kaufmann AM1, McDonald PJ1, Fewer D1, Butler J2,

Results of Definitive Radiotherapy in Anal Canal Carcinoma

Extending intracranial treatment options with Leksell Gamma Knife® Icon™ Key Statements from Customer Perspective by University Medical Centre Mannheim.

Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.

Compassionate People World Class Care

Evaluation Of RTOG Guidelines For Monte Carlo Based Lung SBRT Planning

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases Isabelle Thibault, MD, Mikki Campbell,

Leksell Gamma Knife® Icon™

Daniel E. Roos, B. Sc. (Hons), M. D. , FRANZCR. , Brian P

Tumour-Targeted Treatment Intensification for Prostate Cancer Using Magnetic Resonance Imaging Guidance Jessy Abed, RTT, MHScMRS, Jenny Lee, MMath, Tim.

Fig. 4. Percentage of passing rate between clinical and 544 plans.

Diagnostic Neuroradiology Case

Insert tables Insert graphs Insert figure

Hippocampal-sparing and target volume coverage in treating 3 to 10 brain metastases: A comparison of Gamma Knife, single-isocenter VMAT, CyberKnife, and.

Median Volume (cc) of GTV Receiving Dose

Dosimetry of Alternative Techniques for Accelerated Partial Breast Irradiation Hanh Pham, B.S, CMD, Thanh Nguyen, BS, Christina Henson, MD, Salahuddin.

CK RS for non-resectable pancreatic tumors

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Re-irradiation with VMAT for progressive brain metastases after previous whole brain radiation for radionecrosis risk avoidance. Marilena Theodorou, MD.

Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer Nancy El-Bared, MD,

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Serial axial T2-weighted images (2000/110/2 at treatment, 3400/100/4 at 6 months and 4000/100/3 at 10 months and 36 months after treatment) in a 52-year-old.

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Nicholas Trakul, MD, PhD, Jeremy P

Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability Prashant Gabani, MD, Benjamin W.

Results: Purpose/Objectives: Methods: Conclusions:

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Presentation transcript:

Purpose/Objectives: A percentage of patients receiving stereotactic radiosurgery (SRS)/fractionated stereotactic radiotherapy (FSRT) for Schwannomas initially respond with a transient volumetric enlargement. 1,2 The objective of this study is to evaluate possible predictive factors of transient MRI volumetric changes. Results: Change in tumor size was classified as:  Enlargement  Transient enlargement  Direct shrinkage  Alternating enlargement and regression Nine of the cases (36%) had transient enlargement or alternating enlargement and regression based on post-treatment imaging. The response in original tumor size ranged from 17%-653%. Patients with prior surgical intervention, radiation dose greater than 16Gy, or SRS were more likely to be represented in this population. Blue = Single fraction >16Gy, Brown = FSRT All patients with alternating tumor volume had a history of administered steroids. Conclusions: Results still mandate close post-treatment MRI surveillance for volumetric increase of Schwannomas following SRS/FSRT. Of special concern for transient/alternating increase in volume may be those patients having had prior surgical intervention, higher radiation doses or a single fraction treatment. Volumetric Increase in Schwannomas on Surveillance Brain MRIs Following Stereotactic Radiosurgery: a Review of Predictive Factors Krisha J. Opfermann, MD; S. Lewis Cooper, MD; Joseph M. Jenrette, III, MD Department of Radiation Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, United States Methods: IRB approved retrospective review was undertaken of 25 schwannoma patients treated with definitive radiotherapy at our institution IRB approved retrospective review was undertaken of 25 schwannoma patients treated with definitive radiotherapy at our institution ( ). Patient course consisted of:  Initial MRI  Radiation Oncologist/Neurosurgery consultation  Radiation Therapy:  Follow-up brain MRIs Median: 28 months (2.9mos-158mos) Volumetric changes were measured by a single reviewer on T1-contrasted images. Enlargement based on a >13% increase in volumetric tumor size*. 1,3 * For patients without volumetric data; + 0.2cm change in max diameter. Patients: Patient characteristics, post-treatment symptoms and management were reviewed: References: 1. Nakamura H, Jokura H, Takahashi K, Boku N, Akabane A, Yoshimoto T. Serial Follow- up MR Imaging after Gamma Knife Radiosurgery for Vestibular Schwannoma. American Journal of Neuroradiology 2000; 21: Hirato M, Inoue H, Nakamura M, Ohye C, Hirato J, Shibazaki T, Andou Y. Gamma knife radiosurgery for acoustic schwannoma: early effects and preservation of hearing. Neurologia Medico-Chirurgica(Tokyo) 1995; 35: Meijer O, Weijmans E, Knol D, Slotman B, Barkhof F, Vandertop W, Castelijns J. Tumor-Volume Changes after Radiosurgery for Vestibular Schwannoma: Implications for Follow-Up MR Imaging Protocol. American Journal of Neuroradiology 2008; 29:906 –10. FSRTSRS Linac-based Gamma-knife Time Frame 1/1990-1/19991/1999-1/20111/2011- Current Radiation Source Photon (6MV) Arcs/Beams 193 Cobalt-60 Sources Fractions 311 Gamma-knife treatment plan generated for radiotherapy of an acoustic neuroma. red line = cochlea, blue line = tumor contour, yellow = 12.5Gy IDL, inner green line = 8Gy IDL, outer green line = 3Gy IDL Patient Characteristics General Characteristics Tumors(n)* 25 Median Age(yrs) 49 range(13-82) Sex(n) male12 female13 Race(n) white19 black4 other2 Previous Surgery(n) 0/24 Previous RT(n) 0/24 Steriods Prior(n) 4/23 Co-morbidities HTN(n) 5/22 DM(n) 1/22 NF-2(n) 3/23 Tumor Characteristics Site of Schwannoma(n) acoustic20 Side of Schwannoma(n) left12 right13 Cystic Component(n) 11/23 Median Max diameter(cm)† 2.12 (1-4.27) Median Volume(cm 3 )† 3.12 ( ) Treatment Isocenters(n) 1 (1-3) Rx IDL(%)† 100 ( ) Steriods given within 48hrs 1/21 FSRTSRS Patients(n) 619 Median Total Dose(Gy) 22.5 (21-24)18 (12-25) *1 patient with NF-2 had bilateral tumors treated at differing times. † Data limited for up to 7 patients Volume changes (cm 3 )